192 related articles for article (PubMed ID: 3862071)
21. Clinical correlations of leukemic clonogenic cell chemosensitivity assessed by in vitro continuous exposure to drugs.
Park CH; Wiernik PH; Morrison FS; Amare M; Van Sloten KV; Maloney TR
Cancer Res; 1983 May; 43(5):2346-9. PubMed ID: 6572563
[TBL] [Abstract][Full Text] [Related]
22. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
[No Abstract] [Full Text] [Related]
23. Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance.
Hindenburg AA; Baker MA; Gleyzer E; Stewart VJ; Case N; Taub RN
Cancer Res; 1987 Mar; 47(5):1421-5. PubMed ID: 3469017
[TBL] [Abstract][Full Text] [Related]
24. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Pedersen-Bjergaard J; Brincker H; Ellegaard J; Drivsholm A; Freund L; Jensen KB; Jensen MK; Nissen NI
Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
[TBL] [Abstract][Full Text] [Related]
25. Future clinical investigations with anthracycline antibiotics in relation to daunorubicin.
Muggia FM; Blum RH; Wernz JC
Cancer Treat Rep; 1981; 65 Suppl 4():35-7. PubMed ID: 6955012
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic results with aclacinomycin A in recurring acute leukemias].
Mitrou PS
Onkologie; 1983 Aug; 6(4):192-4. PubMed ID: 6355949
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man.
Buick RN; Messner HA; Till JE; McCulloch EA
J Natl Cancer Inst; 1979 Feb; 62(2):249-55. PubMed ID: 310906
[TBL] [Abstract][Full Text] [Related]
28. A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia.
Goemans BF; Zwaan CM; Reinhardt D; Gibson BE; Hählen K; Kaspers GJ
Haematologica; 2006 Nov; 91(11):1573-4. PubMed ID: 17043024
[TBL] [Abstract][Full Text] [Related]
29. [Differentiation of human promyelocytic leukemic cells (HL-60) induced by aclacinomycin-B].
Lu Y; Han J; Liu HY; Zhong GP; Yang S; Jia TZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1986 Jun; 8(3):211-3. PubMed ID: 2946461
[No Abstract] [Full Text] [Related]
30. Clinical studies with daunorubicin-DNA and adriamycin-DNA complexes: a review.
Trouet A; Sokal G
Cancer Treat Rep; 1979 May; 63(5):895-8. PubMed ID: 287556
[TBL] [Abstract][Full Text] [Related]
31. [In vitro drug-sensitivity test using human tumor clonogenic assay in lung cancer patients].
Ohnoshi T; Hiraki S
Gan To Kagaku Ryoho; 1985 Aug; 12(8):1582-7. PubMed ID: 3927847
[TBL] [Abstract][Full Text] [Related]
32. In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
Kokenberg E; Sonneveld P; Delwel R; Sizoo W; Hagenbeek A; Löwenberg B
Leukemia; 1988 Aug; 2(8):511-7. PubMed ID: 3166077
[TBL] [Abstract][Full Text] [Related]
33. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
34. Interaction of anthracyclines with covalently closed circular DNA.
Mong S; DuVernay VH; Strong JE; Crooke ST
Mol Pharmacol; 1980 Jan; 17(1):100-4. PubMed ID: 6155600
[No Abstract] [Full Text] [Related]
35. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
[TBL] [Abstract][Full Text] [Related]
36. [Adriamycin-aclacinomycin therapy (AA therapy) for acute leukemia unresponsive to BH-AC-DMP therapy].
Kobayashi M; Tahara T
Gan To Kagaku Ryoho; 1983 Jun; 10(6):1473-9. PubMed ID: 6575727
[TBL] [Abstract][Full Text] [Related]
37. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
38. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
[TBL] [Abstract][Full Text] [Related]
39. Relationship between the intracellular accumulation of anthracyclines and effectiveness in vitro and in vivo.
Tapiero H; Munck JN; Fourcade A
Drugs Exp Clin Res; 1986; 12(1-3):257-64. PubMed ID: 3460752
[TBL] [Abstract][Full Text] [Related]
40. [Experimental bases of the in vitro treatment of leukemic bone marrow by a derivative of cyclophosphamide: ASTA Z 7557].
Douay L; Gorin NC; Mary JY; Duhamel G
C R Acad Sci III; 1985; 301(6):303-8. PubMed ID: 3928107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
